Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 187Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 66Neoplasms 62Ovarian Neoplasms 59Glioblastoma 40Carcinoma, Hepatocellular 36Neoplasm Metastasis 32Colonic Neoplasms 27Carcinoma, Renal Cell 24Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 21Rectal Neoplasms 17Pancreatic Neoplasms 17Lung Neoplasms 17Stomach Neoplasms 15Liver Neoplasms 15Brain Neoplasms 14Non-Squamous Non-Small Cell Lung Cancer 13Endometrial Neoplasms 11Recurrence 10Glioma 10Carcinoma, Ovarian Epithelial 10Triple Negative Breast Neoplasms 9Melanoma 9Gastrointestinal Neoplasms 9Advanced Solid Tumors 9Solid Cancers 7Peritoneal Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7

Interventions

XENP 1595 2Cancer Vaccines 2Adjuvants, Immunologic 2veliparib 1glutathione pegylated liposomal doxorubicin 1elacestrant 1binimetinib 1abemaciclib 1Trastuzumab 1Radiosurgery 1RAD1901 1PF-07284890 1Midazolam 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Brain Diseases × Bevacizumab × Clear all
NCT00906516 2009-05-21

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Bradmer Pharmaceuticals Inc.

Phase 2 Unknown
60 enrolled
CNS

Brain Diseases, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡